Chemistry:Enzomenib
From HandWiki
Enzomenib is an investigational new drug that is being evaluated for the treatment of acute leukemia.[1] It is a small molecule inhibitor that targets the interaction between menin and mixed-lineage leukemia (MLL) proteins.[2] Enzomenib particularly in patients with KMT2A (MLL) rearrangements or NPM1 mutations.[3]
The U.S. Food and Drug Administration (FDA) has granted both Fast Track and Orphan Drug designations to Enzomenib.[4]
References
- ↑ "Enzomenib - Sumitomo Pharma". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800058044.
- ↑ "Targeting the undruggable: menin inhibitors ante portas". Journal of Cancer Research and Clinical Oncology 149 (11): 9451–9459. September 2023. doi:10.1007/s00432-023-04752-9. PMID 37103568.
- ↑ "Sumitomo Pharma Presents New Clinical Data on DSP-5336 at the European Hematology Association 2024 Congress". Sumitomo Pharma Co., Ltd.. 14 June 2024. https://news.us.sumitomo-pharma.com/2024-06-14-Sumitomo-Pharma-Presents-New-Clinical-Data-on-DSP-5336-at-the-European-Hematology-Association-2024-Congress.
- ↑ "FDA Grants Fast Track Designation to DSP-5336 in KMT2A/NMP1+ AML". OncLive. 15 July 2024. https://www.onclive.com/view/fda-grants-fast-track-designation-to-dsp-5336-in-kmt2a-nmp1-aml.
 |  |
